Abstract
Various immunological parameters were studied in 100 ovarian cancer patients injected with the OVAREX therapeutic vaccine (the functional component of which is anti-CA125 MAb-B43.13) to explain the serendipitous observation of prolonged survival after such treatment. In addition to CA125-specific humoral and cellular responses, interferon-gamma (IFN-gamma) was also found to be induced in those patients receiving the vaccine. In vitro studies indicated that the expression of MHC I, MHC II, and ICAM I in ovarian tumor cells were upregulated in response to IFN-gamma. Such tumor cells were also found to be more sensitive to CA125-specific cytotoxic T cells compared to cells that were not incubated with IFN-gamma.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / therapeutic use*
-
CA-125 Antigen / immunology*
-
Female
-
Histocompatibility Antigens Class I / metabolism
-
Histocompatibility Antigens Class II / metabolism
-
Humans
-
Intercellular Adhesion Molecule-1 / metabolism
-
Interferon-gamma / metabolism
-
Interferon-gamma / therapeutic use*
-
Mice
-
Mice, Nude
-
Ovarian Neoplasms / immunology
-
Ovarian Neoplasms / therapy*
-
T-Lymphocytes, Cytotoxic / drug effects
-
T-Lymphocytes, Cytotoxic / immunology*
-
Tumor Cells, Cultured
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
CA-125 Antigen
-
Histocompatibility Antigens Class I
-
Histocompatibility Antigens Class II
-
Intercellular Adhesion Molecule-1
-
Interferon-gamma
-
oregovomab